Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Photo

Shorla Oncology at Bio CEO & Investor conference, New York 2022

March 4th 2022February 14th 2022

Read More

Photo

Shorla Oncology at Euronext IPO ready programme, Dublin 2022

March 7th 2022February 14th 2022

Read More

Banner

Shorla Oncology at ASH, Atlanta, Georgia 2021

March 7th 2022December 2nd 2021

Read More

Photo

CEO Sharon Cunningham met with Minister Robert Troy at Enterprise Ireland’s trade visit in Boston

March 7th 2022November 4th 2021

Read More

Banner

Shorla Oncology at CPhI Worldwide in Milan

March 7th 2022November 1st 2021

Read More

Banner

Shorla Oncology at Asembia Specialty Pharmacy Summit

March 7th 2022October 22nd 2021

Read More

Photo

Shorla recently welcomed the Minister of State for Business, Employment and Retail, Damien English to the Clonmel office

March 7th 2022September 24th 2021

Read More

Banner

Shorla Oncology at HLTH Boston 2021

March 7th 2022September 24th 2021

Read More

Banner

Shorla Oncology at Biotech Week Boston

March 7th 2022September 17th 2021

Read More

Older posts
Newer posts
Page1 … Page7 Page8 Page9 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.